The majority of these studies (10 of 13) describe accounts of BRCA2-mutated MBC cases and highlight the significant familial risk and increased lifetime likelihood of developing MBC or prostate cancer in patients with BRCA2 alterations [79,80,82,84,85,86,87,89,91]. The gene discussed is BRCA2; the disease is prostate cancer.